Ponatinib-induced neutrophilic panniculitis.

Abstract

Ponatinib is a bcr-abl tyrosine-kinase inhibitor (TKI) used to treat resistant and refractory chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia that express bcr-abl. Neutrophilic panniculitis has been described in rare cases of patients on other TKIs in the same class as ponatinib. We present the first case of neutrophilic panniculitis following treatment with ponatinib and summarize the other cases of panniculitis caused by TKIs.

• Authors: May Zhang, Khaled M Hassan, Amy Musiek, Ilana S Rosman
• Journal: Journal of cutaneous pathology (J Cutan Pathol) Vol. 41 Issue 7 Pg. 597-601 (Jul 2014) ISSN: 1600-0560 [Electronic] United States
• PMID: 24602068 (Publication Type: Case Reports, Journal Article)
• Copyright: © 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Chemical References

• Imidazoles
• Protein Kinase Inhibitors
• Pyridazines
• ponatinib
• Fusion Proteins, bcr-abl

Topics

• Female
• Fusion Proteins, bcr-abl (antagonists & inhibitors)
• Humans
• Imidazoles (administration & dosage, adverse effects)
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy, pathology)
• Middle Aged
• Neutrophils (pathology)
• Panniculitis (chemically induced, pathology)
• Protein Kinase Inhibitors (administration & dosage, adverse effects)
• Pyridazines (administration & dosage, adverse effects)